C4 Therapeutics (CCCC) Enterprise Value (2019 - 2026)

C4 Therapeutics' Enterprise Value history runs 8 years deep, the most recent figure standing at -$235.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 9.57% year-over-year to -$235.7 million; the TTM figure through Mar 2026 stood at -$235.7 million (down 9.57% YoY), while the FY2025 annual figure was -$248.5 million, down 1.48% from the prior year.
• Enterprise Value was -$235.7 million for Q1 2026 at C4 Therapeutics, up from -$248.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$191.9 million in Q3 2025 to a low of -$313.7 million in Q3 2022.
• Historically, Enterprise Value has averaged -$254.4 million across 5 years, with a median of -$255.6 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value soared 33.94% in 2022, then declined 18.04% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$276.2 million in 2022, then increased by 8.14% to -$253.7 million in 2023, then increased by 3.46% to -$244.9 million in 2024, then decreased by 1.48% to -$248.5 million in 2025, then advanced by 5.18% to -$235.7 million in 2026.
• The last three Enterprise Value figures came in at -$235.7 million (Q1 2026), -$248.5 million (Q4 2025), and -$191.9 million (Q3 2025), per Business Quant data.